Liposomal formulations for enhanced lymphatic delivery

Asian Journal of Pharmaceutical Sciences

Volumn 8, Issue 2, 2013, Pages 100-109

  Kim, Hyeongmin ^a   Kim, Yeongseok ^a   Lee, Jaehwi ^a  

^a Chung Ang University   (South Korea)

Author keywords

Bioavailability; Liposome; Lymphatic drug delivery

Indexed keywords

CALCITONIN; CATECHIN; CEFOTAXIME; CHYLOMICRON; CLOZAPINE; CYCLOSPORIN; HALOFANTRINE; LIPOSOME; NANOPARTICLE; RALOXIFENE; RECOMBINANT EPIDERMAL GROWTH FACTOR; SOLID LIPID NANOPARTICLE; TOBRAMYCIN; VINPOCETINE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSPORT; EMULSION; FIRST PASS EFFECT; HUMAN; HYDROPHOBICITY; INTESTINE ABSORPTION; INTESTINE CELL; INTESTINE LYMPH; LIPID ABSORPTION; LIPOPHILICITY; MALARIA; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY;

EID: 84881343005     PISSN: 18180876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Charman WN, Stella VJ. Estimating the maximum potential for intestinal lymphatic transport of lipophillic drug molecules. Int J Pharm. 1986, 34: 175-178.
2. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008, 60: 702-716.
3. Lalanne M, Paci A, Andrieux K, et al. Synthesis and biological evaluation of two glycerolipidicprodrugs of didanosine for direct lymphatic delivery against HIV. Bioorg Med ChemLett. 2007, 17: 2237-2240.
4. Garzon-Aburbeh A, Poupaert JH, Claesen M, et al. 1,3-dipalmitoylglycerol ester of chlorambucil as a lymphotropic, orally administrable antineoplastic agent. J Med Chem. 1983, 26: 1200-1203.
5. Cense HA, van Eijck CH, Tilanus HW. New insights in the lymphatic spread of oesophageal cancer and its implications for the extent of surgical resection. Best Pract Res ClinGastroenterol. 2006, 20: 803-906.
6. Arya M, Bott SR, Shergill IS et al. The metastatic cascade in prostate cancer. SurgOncol. 2006, 15: 117-128.
7. Muranishi S. Lymphatic delivery of drugs and its application to cancer chemotherapy. (author's transl), YakugakuZasshi. 1980, 100: 687-698.
8. Humberstone AJ, Charman WN. Lipid-based vehicles for oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev. 1997, 25: 103-128.
9. Tso P. Intestinal lipid absorption. In: Johnson, L.R. (Ed.). Physiology of the Gastrointestinal Tract, 3rd Edition. Raven Press, New York. 1994: 1867-1907.
10. Porter CJH, Charman WN. Uptake of drugs into the intestinal lymphatics after oral administration. Adv Drug Deliv Rev. 1997, 25: 71-89.
11. Caliph SM, Charman WN, Porter CJH. Effect of short-, medium-, and long-chain fatty acid based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci. 2000, 89: 1073-1084.
12. Cai S, Yang Q, BagbyTR, et al. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliver Rev. 2011, 63:901-908.
13. Yáñez JA, Wang SWJ, Knemeyer IW, et al. Intestinal lymphatic transport for drug delivery. Adv Drug Deliver Rev. 2011, 63:923-942.
14. Lembo D, Cavalli R. Nanoparticulate delivery systems for antiviral drugs. AntivirChemChemoth. 2010, 21:53-70.
15. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000, 50: 161-177.
16. Mehnert W, Mäder K. Solid lipid nanoparticles Production, characterization and applications. Adv Drug Deliver. Rev. 2012, 47: 165-196.
17. Manjunath K, Reddy JS, Venkatateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release. 2005, 107: 215-228.
18. Cavalli R, Zara GP, Caputo O, et al. Transmucosal transport of tobramycin incorporated in SLN after duodenal administration to rats. Part I-A pharmacokinetic study. Pharmacol Res. 2000, 42: 541-545.
19. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004, 58: 173-182.
20. Holm R, Porter CJ, Edwards GA, et al. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self496 oemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. Eur J Pharm Sci. 2003, 20: 91-97
21. Thakkar H, Nangesh J, Parmar M, et al. Formulation and characterization of lipid-based drug delivery system of raloxifene-microemulsion and self-microemulsifying drug delivery system. J Pharm Bioallied Sci. 2011, 3: 442-448
22. Chen Y, Li G, Wu X, et al. Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: formulation development and in vivo assessment. Biol Pharm Bull. 2008, 31: 118-125.
23. Hauss DJ, Fogal SE, Ficorilli JV, et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci. 1998, 87: 164-169.
24. Ling SS, Magosso E, Khan NA, et al. Enhanced oral bioavailability and intestinal lymphatic transport of a hydrophilic drug using liposomes. Drug DevInd Pharm. 2006, 32: 335-345.
25. Perrie Y, Obrenovic M, McCarthy D, et al. Liposome (Lipodine)- mediated DNA vaccination by the oral route. J Liposome Res. 2002, 12: 185-197.
26. Maghraby GM El, Williams AC, Barry BW. Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm. 2004, 276: 143-161.
27. Godin B, Touitou E. Mechanism of bacitracin permeation enhancement through the skin and cellular membranes from an ethosomal carrier. J Control Release. 2004, 94: 365-379.
28. Fang JY, Hwang TL, Huang YL, et al. Enhancement of the transdermal delivery of catechins by liposomes incorporating anionic surfactants and ethanol. Int J Pharm. 2006a, 310: 131-138.
29. Hashida N, Murakami M, Yoshikawa H, et al. Intestinal absorption of carboxyfluorescein entrapped in liposomes in comparison with its administration with lipid- surfactant mixed micelles. J Pharmacobiodyn. 1984, 7: 195-203.
30. Huang YB, Tsai MJ, Wu PC, et al. Elastic liposomes as carriers for oral delivery and the brain distribution of (+)-catechin. J Drug Target. 2011, 19: 709-718.
31. Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001, 19: 2965-2974.
32. Shukla A, Khatri K, Gupta PN, et al. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharmaceut Sci. 2008, 11: 58-66.
33. Mann JFS, Ferro VA, Mullen AB, et al. Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin. Vaccine. 2004, 22: 2425-2429.
34. Guan P, Lu Y, Qi J, et al. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine. 2011, 6: 965-974.
35. Takeuchi H, Matsui Y, Yamamoto H, et al. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in oral administration of calcitonin to rats. J Control Release. 2003, 86:235-242.
36. Kim HJ, Lee CM, Lee YB, et al. Preparation and Mucoadhesive Test of CSA-loaded Liposomes with Different Characteristics for the Intestinal Lymphatic Delivery. BIOTECHNOL BIOPROC E. 2005, 10: 516-521.
37. Michalek SM, Childers NK, Katz J, et al. Liposomes as oral adjuvants. Curr Top MicrobiolImmunol. 1989, 146:51-58.
38. Li H, Son JH, Park JS, et al. Polyethyleneglycol-coated liposomes for oral delivery of recombinant human epidermal growth factor. Int J Pharm. 2003, 258: 11-19.
39. Iwanaga K, Ono S, Narioka K, et al. Oral delivery of insulin by using surface coating liposomes improvement of stability of insulin in GI tract. Int J Pharm. 1997, 157: 73-80.
40. Iwanaga K, Ono S, Narioka K, et al. Application of surface-coated liposomes for oral delivery of peptide: effect of coating the liposome's surface on the GI transit of insulin. J Pharm Sci. 1999, 88:248-252.
41. Moribe K, Maruyama K, Iwatsuru M. Encapsulation cha- racteristics of nystatin in liposomes: effect of cholesterol and polyethylene glycol derivatives. Int J Pharm. 1999, 188: 193-202.
42. Rubas W, Banerjea AC, Gallati H, et al. Incorporation of the reovirus M cell attachment protein into small unilamellar vesicles: incorporation efficiency and binding capability to L929 cells in vitro. J Microencapsul. 1990, 7:385-95.
43. Myers RA. Stella VJ. Factors affecting the lymphaic transport of penclomedine(NSC- 338720), a lipophilic cytotoxic drug: comparison to DDT and hexachlorobenzene. Int J Pharm. 1992, 80: 511-562.
44. Hauss DJ, Mehta SC, Radebaugh GW. Targeted lymphatic transport andmodified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via aformulation approach. Int J Pharm. 1994, 108: 85-93.
45. Khoo SM, Porter CJH, Edwards GA, et al. Intestinal lymphatic transport is the primary route for halofantrine afteroral postprandial administration. Pharm Sci. 1999, 1: S-624.
46. Dagett PR, Wheeler MJ, Naborro JDN. Oraltestosterone, a reappraisal. Hormone Res. 1978, 9: 121-129.
47. Tauber U, Schroder K, Dusterberg B, et al. Absolute bioavailability of testosterone after oraladministration of testosterone-undecanoate and testosterone. Eur J Drug MetabPharmacokin. 1986, 11: 145-149.
48. Ichihashi T, Kinoshita H, Takagishi Y, et al. Effect of oily vehicles on absorption of mepitiostaneby the lymphatic system in rats. J Pharm Pharmacol.1992, 44: 560-564.
49. Ichihashi T, Kinoshita H, Takagishi Y, et al. Effect of bile on absorption of mepitiostane by thelymphatic system in rats. J PharmPharmacol. 1992, 44: 566-569.
50. Ichihashi T, Kinoshita H, Takagishi Y, et al. Intrinsic lymphatic partition rate of mepitiostane, epitiostanol and oleic acid absorbed from rat intestine. PharmRes. 1991, 8: 1302-1306.
51. Sugihara J, FuruuchiS, Ando H, et al. Studies on the intestinal lymphaticabsorption of drugs. II. Glyceride prodrugs for improving thelymphatic absorption of naproxen and nicotinic acid. JPharmacobio-Dyn. 1998, 11: 555-562.
52. Mizobe M, Matsuda S, Yoneyama T, et al. Evaluation of the bioavailability of hypolipidemiccompound, LK-903. Chem Pharm Bull. 1983, 31: 2424-2431.
53. Deverre JR, LoiseauP, Couvreur P, et al. In vitro evaluation offilaricidal activity of GABA and 1,3-dipalmitoyl-2-(4-aminobutyryl)glycerol. HCl: a diglycerideprodrug. J Pharm Pharmacol. 1989, 41: 191-193.
54. Jacob JN, Hesse GW, Shashoua VE. Synthesis, brain uptake and pharmacological properties of aglyceryl lipid containing GABA and the GABA-T inhibitor, y-vinyl-GABA. J Med Chem. 1990, 33: 733-736.
55. Garzon-Abureh A, Poupaert JH, Claesen M, et al. A lymphotropicprodrug of L-Dopa: Synthesis, pharmacological properties and pharmacokinetic behavior of1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)propanoyl]propane- 1,2,3-trio]. J Med Chem. 1986, 29: 687-691.
56. Garzon-Abureh A, Poupaert JH, Claesen M, et al. 1,3-Dipalmitoylglycerol ester ofchlorambucil as a lymphotropic, orally administrable antineoplasticagent. J Med Chem. 1983, 26: 1200-1203
57. Sakai A, Mori N, Shuto S, et al. Deacylation-reacylation cycle: a possibleabsorption mechanism for the novel lymphotropic antitumor agent dipalmitoylphosphatidylfluorouridine in rats. J Pharm Sci. 1993, 82: 575-578.